121 related articles for article (PubMed ID: 314367)
1. Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly sequential study of melanoma patients. I. Changes in non-specific (NK, K and T cell) lymphocytotoxicity, peripheral blood counts and delayed hypersensitivity reactions.
Thatcher N; Swindell R; Crowther D
Clin Exp Immunol; 1979 May; 36(2):227-36. PubMed ID: 314367
[TBL] [Abstract][Full Text] [Related]
2. Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma. A sequential study over 28 days. II. Changes in non-specific (NK, K and T cell) lymphocytoxicity and delayed hypersensitivity skin reactions.
Thatcher N; Swindell R; Crowther D
Clin Exp Immunol; 1979 Feb; 35(2):171-9. PubMed ID: 312169
[TBL] [Abstract][Full Text] [Related]
3. Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma a sequential study over 28 days. I. Changes in blood counts, serum immunoglobulins and lymphoid cell populations.
Thatcher N; Swindell R; Crowther D
Clin Exp Immunol; 1979 Jan; 35(1):36-44. PubMed ID: 428146
[TBL] [Abstract][Full Text] [Related]
4. Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly study of melanoma patients II. Changes in serum immunoglobulins and lymphoid cell subpopulations.
Thatcher N; Swindell R; Crowther D
Clin Exp Immunol; 1979 Jun; 36(3):456-64. PubMed ID: 487647
[TBL] [Abstract][Full Text] [Related]
5. Effects of BCG and Corynebacterium parvum on immune reactivity in melanoma patients.
Thatcher N; Crowther D
Dev Biol Stand; 1977 Apr 13-15; 38():449-53. PubMed ID: 608536
[TBL] [Abstract][Full Text] [Related]
6. Effects of diphenylhydantoin on killer cell activity and other immunological functions. A sequential study including the interaction of Corynebacterium parvum in melanoma patients.
Thatcher N; Wan HH; Swindell R; Wilkinson PM; Crowther D
Int J Immunopharmacol; 1982; 4(3):167-74. PubMed ID: 7107099
[TBL] [Abstract][Full Text] [Related]
7. The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment.
Guillot B; Portalès P; Thanh AD; Merlet S; Dereure O; Clot J; Corbeau P
Br J Dermatol; 2005 Apr; 152(4):690-6. PubMed ID: 15840100
[TBL] [Abstract][Full Text] [Related]
8. Activation of peritoneal lymphocyte cytotoxicity in patients with ovarian cancer by intraperitoneal treatment with Corynebacterium parvum.
Lichtenstein A; Berek J; Bast R; Spina C; Hacker N; Knapp RC; Zighelboim J
J Biol Response Mod; 1984 Aug; 3(4):371-8. PubMed ID: 6541243
[TBL] [Abstract][Full Text] [Related]
9. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response.
Barth A; Hoon DS; Foshag LJ; Nizze JA; Famatiga E; Okun E; Morton DL
Cancer Res; 1994 Jul; 54(13):3342-5. PubMed ID: 8012946
[TBL] [Abstract][Full Text] [Related]
10. Systemic administration of human leukocyte interferon to melanoma patients. III. Increased helper:suppressor cell ratios in melanoma patients during interferon treatment.
Karavodin LM; Golub SH
Nat Immun Cell Growth Regul; 1983-1984; 3(4):193-202. PubMed ID: 6241293
[TBL] [Abstract][Full Text] [Related]
11. [Monitoring natural killer cell activity in the blood of patients with malignant pleural effusion after intrapleural administration of Corynebacterium parvum].
Marel M; Pospísil M; Fiserová A; Melínová L; Skácel Z; Bednár M
Cas Lek Cesk; 1990 Apr; 129(16):498-500. PubMed ID: 2340567
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of experimental tumor metastasis by selective activation of natural killer cells.
Hanna N
Cancer Res; 1982 Apr; 42(4):1337-42. PubMed ID: 6277482
[TBL] [Abstract][Full Text] [Related]
13. In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2.
Schomburg A; Menzel T; Körfer A; Heer G; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
Nat Immun; 1992; 11(3):133-43. PubMed ID: 1392401
[TBL] [Abstract][Full Text] [Related]
14. Suppression of natural killer cell cytotoxicity by splenocytes from Corynebacterium parvum-injected, bone marrow-tolerant, and infant mice.
Savary CA; Lotzová E
J Immunol; 1978 Jan; 120(1):239-43. PubMed ID: 342602
[TBL] [Abstract][Full Text] [Related]
15. Surgical adjuvant therapy of malignant melanoma with corynebacterium parvum.
Hilal EY; Pinsky CM; Hirshaut Y; Wanebo HJ; Hansen JA; Braun DW; Fortner JG; Oettgen HF
Cancer; 1981 Jul; 48(2):245-51. PubMed ID: 7016302
[TBL] [Abstract][Full Text] [Related]
16. Stimulation of the non-specific resistance by Corynebacterium parvum and Bacillus calmette Guérin.
Ruitenberg EJ; Steerenberg PA
Tijdschr Diergeneeskd; 1976 Jul; 101(14):775-8. PubMed ID: 821172
[TBL] [Abstract][Full Text] [Related]
17. Anti-T antibody in malignant melanoma patients. Influence of response and survival following chemotherapy--changes in serum levels following C parvum, BCG immunization.
Thatcher N; Hashmi K; Chang J; Swindell R; Crowther D
Cancer; 1980 Sep; 46(6):1378-82. PubMed ID: 7417939
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of immunotherapeutic efficacy of BCG and mw vaccines in patients of borderline lepromatous and lepromatous leprosy.
Narang T; Kaur I; Kumar B; Radotra BD; Dogra S
Int J Lepr Other Mycobact Dis; 2005 Jun; 73(2):105-14. PubMed ID: 16830653
[TBL] [Abstract][Full Text] [Related]
19. Comparative study on the effects of recombinant alpha-2 interferon on immune function in patients with disseminated melanoma.
Hersey P; Coates A; Rallings M; Hall C; MacDonald M; Spurling A; Edwards A; McCarthy WH; Milton GW
J Biol Response Mod; 1986 Jun; 5(3):236-49. PubMed ID: 3487622
[TBL] [Abstract][Full Text] [Related]
20. Effects of Corynebacterium parvum on cellular immunity of cancer patients, assayed sequentially over 63 days.
Thatcher N; Lamb B; Swindell R; Crowther D
Cancer; 1981 Jan; 47(2):285-90. PubMed ID: 7459817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
